A Phase III, Randomised, Double-blind, Placebo-controlled, Multi-centre, International Study of MEDI4736 as Sequential Therapy in Patients with Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Definitive, Platinum-based, Concurrent Chemoradiation Therapy (PACIFIC) (Protocol# D4191C00001)
ID Number 16-0451Principal Investigator(s)
Department(s) or Division(s)
Hematology and Medical Oncology
This study is being carried out to see if MEDI4736 (referred to as the "study drug" from now on) is effective and safe in treating lung cancer.
This will be done by seeing if the study drug prolongs or improves the benefit you have already received from your initial treatment with chemotherapy and radio therapy. To do this a comparison will be made between patients who receive the study drug and patients who receive placebo (a "dummy treatment" that looks like the study drug but contains no active ingredient). The study drug or placebo will be given after you have received chemotherapy and radiotherapy and your cancer has shown some improvement or has stabilized with this previous treatment.
Recruiting Patients: No